Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in Childhood-onset Systemic Lupus Erythematosus
NCT05687526Phase 1Completed
- Sponsor
- RemeGen
- Start
- May 2023
- Primary completion
- Nov 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of telitacicept in systemic lupus erythematosus (SLE), sponsored by RemeGen. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 5 more. Started May 2023; status: completed.
02
Drugs
telitacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05687526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05687526.